Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives

Neelufar Mozaffarian,1 Steve Lobosco,2 Peng Lu,3 Adam Roughley,2 Gabriela Alperovich4 1Clinical Development, AbbVie Inc., North Chicago, USA; 2Adelphi Real World Ltd., Macclesfield, UK; 3Clinical Development, AbbVie Inc., Worcester, MA, USA; 4Global Medical Affairs Immunology, AbbVie Inc., Madrid,&...

Full description

Bibliographic Details
Main Authors: Mozaffarian N, Lobosco S, Lu P, Roughley A, Alperovich G
Format: Article
Language:English
Published: Dove Medical Press 2016-10-01
Series:Patient Preference and Adherence
Subjects:
Online Access:https://www.dovepress.com/satisfaction-with-control-of-systemic-lupus-erythematosus-and-lupus-ne-peer-reviewed-article-PPA
id doaj-4ad9e061594a4bcbbe5f0ecfbca745d9
record_format Article
spelling doaj-4ad9e061594a4bcbbe5f0ecfbca745d92020-11-24T23:32:43ZengDove Medical PressPatient Preference and Adherence1177-889X2016-10-01Volume 102051206129261Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectivesMozaffarian NLobosco SLu PRoughley AAlperovich GNeelufar Mozaffarian,1 Steve Lobosco,2 Peng Lu,3 Adam Roughley,2 Gabriela Alperovich4 1Clinical Development, AbbVie Inc., North Chicago, USA; 2Adelphi Real World Ltd., Macclesfield, UK; 3Clinical Development, AbbVie Inc., Worcester, MA, USA; 4Global Medical Affairs Immunology, AbbVie Inc., Madrid, Spain Purpose: Patient satisfaction with disease control of systemic lupus erythematosus (SLE) is an important component of medical management. This analysis evaluated patient and physician satisfaction with disease control of SLE, factors associated with satisfaction/dissatisfaction, and the degree of physician–patient concordance of these parameters. Patients and methods: Data were extracted from the US Adelphi Real World Lupus Disease Specific Programme®, a cross-sectional survey of 50 rheumatologists, 25 nephrologists, and their patients with non-nephritis SLE (NNSLE) or lupus nephritis (LN). Results: Physicians reported moderate or severe disease activity in 25.0% of patients with NNSLE and in 50.5% of patients with LN, and were satisfied with disease control in 78.6% (132/168) and 73.8% (152/206) of patients, respectively. For patients, 75.8% (75/99) with NNSLE were satisfied with their current treatment, compared with 65.5% (74/113) with LN. Physician–patient agreement (70.7%) on the level of satisfaction was “slight” (kappa =0.1445) for NNSLE; patients were more frequently dissatisfied than physicians with regard to joint tenderness, fatigue, anxiety, pain on movement, malar rash, and photosensitivity. Physician–patient agreement (71.4%) on the level of satisfaction was “fair” (kappa =0.3695) for LN; patients expressed greater dissatisfaction than physicians for headache, photosensitivity, and anxiety, whereas physicians were more dissatisfied with regard to joint swelling, kidney function, and blood pressure control. In general, patients with NNSLE or LN who were dissatisfied (or whose physicians were dissatisfied) were more likely to have joint swelling, joint stiffness, malar rash, hair loss, depression, and fatigue, have moderate or severe disease, or to be currently experiencing disease flare. Conclusion: These data highlight the patient and physician dissatisfaction with real-world disease control of SLE. Keywords: lupus, satisfaction, concordance, agreement, disease controlhttps://www.dovepress.com/satisfaction-with-control-of-systemic-lupus-erythematosus-and-lupus-ne-peer-reviewed-article-PPALupussatisfactionconcordanceagreementdisease control
collection DOAJ
language English
format Article
sources DOAJ
author Mozaffarian N
Lobosco S
Lu P
Roughley A
Alperovich G
spellingShingle Mozaffarian N
Lobosco S
Lu P
Roughley A
Alperovich G
Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
Patient Preference and Adherence
Lupus
satisfaction
concordance
agreement
disease control
author_facet Mozaffarian N
Lobosco S
Lu P
Roughley A
Alperovich G
author_sort Mozaffarian N
title Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
title_short Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
title_full Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
title_fullStr Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
title_full_unstemmed Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
title_sort satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
publisher Dove Medical Press
series Patient Preference and Adherence
issn 1177-889X
publishDate 2016-10-01
description Neelufar Mozaffarian,1 Steve Lobosco,2 Peng Lu,3 Adam Roughley,2 Gabriela Alperovich4 1Clinical Development, AbbVie Inc., North Chicago, USA; 2Adelphi Real World Ltd., Macclesfield, UK; 3Clinical Development, AbbVie Inc., Worcester, MA, USA; 4Global Medical Affairs Immunology, AbbVie Inc., Madrid, Spain Purpose: Patient satisfaction with disease control of systemic lupus erythematosus (SLE) is an important component of medical management. This analysis evaluated patient and physician satisfaction with disease control of SLE, factors associated with satisfaction/dissatisfaction, and the degree of physician–patient concordance of these parameters. Patients and methods: Data were extracted from the US Adelphi Real World Lupus Disease Specific Programme®, a cross-sectional survey of 50 rheumatologists, 25 nephrologists, and their patients with non-nephritis SLE (NNSLE) or lupus nephritis (LN). Results: Physicians reported moderate or severe disease activity in 25.0% of patients with NNSLE and in 50.5% of patients with LN, and were satisfied with disease control in 78.6% (132/168) and 73.8% (152/206) of patients, respectively. For patients, 75.8% (75/99) with NNSLE were satisfied with their current treatment, compared with 65.5% (74/113) with LN. Physician–patient agreement (70.7%) on the level of satisfaction was “slight” (kappa =0.1445) for NNSLE; patients were more frequently dissatisfied than physicians with regard to joint tenderness, fatigue, anxiety, pain on movement, malar rash, and photosensitivity. Physician–patient agreement (71.4%) on the level of satisfaction was “fair” (kappa =0.3695) for LN; patients expressed greater dissatisfaction than physicians for headache, photosensitivity, and anxiety, whereas physicians were more dissatisfied with regard to joint swelling, kidney function, and blood pressure control. In general, patients with NNSLE or LN who were dissatisfied (or whose physicians were dissatisfied) were more likely to have joint swelling, joint stiffness, malar rash, hair loss, depression, and fatigue, have moderate or severe disease, or to be currently experiencing disease flare. Conclusion: These data highlight the patient and physician dissatisfaction with real-world disease control of SLE. Keywords: lupus, satisfaction, concordance, agreement, disease control
topic Lupus
satisfaction
concordance
agreement
disease control
url https://www.dovepress.com/satisfaction-with-control-of-systemic-lupus-erythematosus-and-lupus-ne-peer-reviewed-article-PPA
work_keys_str_mv AT mozaffariann satisfactionwithcontrolofsystemiclupuserythematosusandlupusnephritisphysicianandpatientperspectives
AT loboscos satisfactionwithcontrolofsystemiclupuserythematosusandlupusnephritisphysicianandpatientperspectives
AT lup satisfactionwithcontrolofsystemiclupuserythematosusandlupusnephritisphysicianandpatientperspectives
AT roughleya satisfactionwithcontrolofsystemiclupuserythematosusandlupusnephritisphysicianandpatientperspectives
AT alperovichg satisfactionwithcontrolofsystemiclupuserythematosusandlupusnephritisphysicianandpatientperspectives
_version_ 1725533559676993536